临床药师开展药学宣教对恶性肿瘤患者用药情况及生活质量的影响

摘要
图/表
参考文献(23)
相关文章 (15)

全文: PDF (440 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨临床药师开展药学宣教对恶性肿瘤患者用药情况及生活质量的影响。方法选取2020年8月至2021年7月溧阳市人民医院肿瘤内科收治的177例恶性肿瘤患者作为研究对象，采用随机数字表法将其分为观察组（88例）与对照组（89例）。对照组患者由医护人员进行传统宣教，观察组患者由临床药师进行详细的个体化用药宣教。比较两组患者的用药知识评分、癌痛知识评分、Morisky服药依从性量表（MMAS-4）评分、药品不良反应总发生率以及肿瘤患者生活质量评分量表（QOL）评分。结果宣教前，两组患者的用药知识、癌痛知识、MMAS-4评分比较，差异无统计学意义（P＞0.05）；宣教后，两组患者的用药知识、癌痛知识评分高于宣教前，MMAS-4评分低于宣教前，差异有统计学意义（P＜0.05）；宣教后，观察组患者的用药知识、癌痛知识评分高于对照组，MMAS-4评分低于对照组，差异有统计学意义（P＜0.05）。观察组患者的药品不良反应总发生率低于对照组，差异有统计学意义（P＜0.05）。宣教前，两组患者的QOL各项评分比较，差异无统计学意义（P＞0.05）；宣教后，两组患者的食欲、精神、睡眠、疲乏、疼痛、家庭理解与配合、自身对癌症的认识、对治疗的态度、日常生活、治疗的副作用、面部表情评分均高于宣教前，且观察组评分高于对照组，差异有统计学意义（P＜0.05）。结论恶性肿瘤患者在治疗过程中由临床药师对其进行药学宣教能够提升患者用药、癌痛相关知识的掌握程度与用药依从性，降低药品不良反应发生率，提高生活质量。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	葛丹亘
	汤杰

关键词 ：恶性肿瘤, 抗肿瘤, 药学宣教, 依从性, 生活质量

Abstract：Objective To explore the effect of pharmaceutical education carried out by clinical pharmacists on medication use and quality of life of patients with malignant tumors. Methods A total of 177 patients with malignant tumor treated in People′s Hospital of Liyang City from August 2020 to July 2021 were selected as research subjects, and they were divided into observation group (88 cases) and control group (89 cases) by random number table method. Patients in the control group received traditional education from medical staff, and patients in the observation group received detailed individualized medication education from clinical pharmacists. Medication knowledge score, cancer pain knowledge score, Morisky medication adherence scale (MMAS-4) score, total incidence of adverse drug reactions and quality of life rating scale (QOL) score of cancer patients were compared between the two groups. Results Before education, there were no statistically significant differences in medication knowledge, cancer pain knowledge and MMAS-4 score between the two groups (P>0.05). After education, scores of medication knowledge and cancer pain knowledge in the two groups were higher than those before education, and MMAS-4 score was lower than that before education, and the diffferences were statistically significant (P<0.05). After education, scores of medication knowledge and cancer pain knowledge in observation group were higher than those in control group, while MMAS-4 score was lower than that in control group, the differences were statistically significant (P<0.05). The total incidence of adverse drug reactions in observation group was lower than that in control group, the difference was statistically significant (P<0.05). Before education, there was no statistically significant difference in QOL scores between the two groups (P>0.05). After education, the scores of appetite, spirit, sleep, fatigue, pain, family understanding and cooperation, understanding of cancer, attitude of treatment, daily life, the side effects of treatment, facial expressions were higher than those before education, and the scores of observation group were higher than those of the control group, the differences were statistically significant (P<0.05). Conclusion Pharmaceutical education by clinical pharmacists in the treatment of malignant tumor patients can improve the mastery of medication use and cancer pain related knowledge and medication compliance, reduce the incidence of adverse drug reactions and improve the quality of life.

Key words： Malignant tumor Antitumor Pharmaceutical education Compliance Quality of life

引用本文:

葛丹亘；汤杰. 临床药师开展药学宣教对恶性肿瘤患者用药情况及生活质量的影响[J]. 中国当代医药, 2022, 29(19): 124-128.
GE Dangen； TANG Jie. Effect of pharmaceutical education carried out by clinical pharmacists on medication use and quality of life of patients with malignant tumors. 中国当代医药, 2022, 29(19): 124-128.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2022/V29/I19/124

[1]	Feng R，Zong Y，Cao S，et al.Current cancer situation in China：good or bad news from the 2018 Global Cancer Statistics?[J].Cancer Commun （Lond），2019，39（1）：22.
[2]	盛玉青，李琦恒，王艳，等.综合干预促进肿瘤辅助治疗药物的合理使用[J].药学与临床研究，2019，27（3）：237-240.
[3]	寇炜，郭代红，田小燕，等.抗肿瘤药致不良反应15 183例分析[J].中国药房，2018，29（4）：508-511.
[4]	方元，瑜悦，吴大维，等.肿瘤免疫治疗中不可忽视的免疫相关不良反应[J].中华肿瘤杂志，2020（1）：17-21.
[5]	Arnaud-Coffin P，Maillet D，Gan HK，et al.A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors[J].Int J Cancer，2019，145（3）：639-648.
[6]	贾燕宁，王瑞，卞元清，等.临床药师参与良性前列腺增生治疗的效果评价[J].中国药房，2021，32（16）：2035-2039.
[8]	张莉，邢亚群，江洁美，等.安罗替尼致高血压的研究进展[J].中国新药杂志，2020，29（20）：2351-2357.
[9]	颜文，王淑琼，薛琴，等.应用Morisky服药依从性量表调查中存在的问题及对策[J].护理研究，2015，29（3）：890-891.
[10]	李凌江，杨德森，周亮，等.世界卫生组织生活质量问卷在中国应用的信度及效度研究[J].中华精神科杂志，2003，36（3）：143-147.
[7]	Si X，Zhang L，Wang H，et al.Management of anlotinib-re-lated adverse events in patients with advanced non-small cell lung cancer：experiences in ALTER-0303[J].Thorac Cancer，2019，10（3）：551-556.
[11]	徐苏慧，李丽.肿瘤化疗患者院外服药依从性与疾病认知的关系及护理对策[J].现代实用医学，2019，31（1）：121-123.
[12]	涂廷延，王长青，许小菊，等.我院癌痛控制现状的调查研究[J].中国当代医药，2019，26（34）：158-160.
[13]	于文华，陆宇晗，杨红，等.肿瘤科护士癌症疼痛管理的态度和知识现状及影响因素的研究[J].中华现代护理杂志，2020，26（18）：2460-2465.
[14]	李丹，孙娟华，邹春芳，等.肿瘤科护理人员癌症疼痛管理的知识和态度调查分析[J].中国实用护理杂志，2019， 35（21）：1651-1656.
[15]	陈婷婷.肿瘤科护理人员癌症疼痛管理的知识和态度调查分析[J].人人健康，2020（9）：174.
[16]	徐春燕，许克璞.疼痛护理干预对恶性肿瘤患者癌痛程度和生存质量的影响[J].首都食品与医药，2020，27（3）：158-159.
[17]	Reta A，Dashtaei A，Lim S，et al.Opportunities to improve clinical outcomes and challenges to implement clinical pharmacists into health care teams[J].Prim Care，2012，39（4）：615-626.
[18]	郭志磊，王为，王志红，等.临床药师参与痛风慢病管理的效果评价：一项前瞻性随机对照研究[J].医药导报，2020，39（2）：164-168.
[19]	何苗苗，刘光斌.临床药师对肿瘤患者的用药教育实践[J].甘肃医药，2018，37（12）：1120-1123.
[20]	薛建辉，唐小慧，曹小花.临床药师干预对抗肿瘤药物临床合理应用的效果[J].临床合理用药，2021，14（4）：156-158.
[21]	胡芸芸，张夏兰，沈夕坤，等.中药临床药师对肿瘤科药物相关问题的分析与探讨[J].中国医药科学，2021，11（24）：133-136，141.
[22]	郑飞浪，程林忠.临床药师对1例子宫内膜癌伴骨转移患者的用药分析[J].中国医药科学，2020，10（20）：241-243，250.
[23]	温坚坤，黄享贞，甄炬荃.临床药师处方审核对静脉配置中心抗肿瘤药物不合理医嘱干预效果分析[J].中国当代医药，2020，27（7）：175-177.